Robert Laliberte
University of Pennsylvania
20 Papers
105 Citations
Robert Laliberte is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 6, co-authored 11 publications.
Chat about Author
Papers
Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors
Toshio Shimizu,Patricia LoRusso,Kyri Papadopoulos,Amita Patnaik,Muralidhar Beeram,Lon Smith,Drew W. Rasco,Theresa Mays,Glenda Chambers,Anna Ma,Jing Wang,Robert Laliberte,Maurizio Voi,Anthony W. Tolcher +13 more
TL;DR: CUDC-101 administered by 1-hour i.v. infusion for 5 consecutive days every 2 weeks was generally well tolerated with preliminary evidence of antitumor activity and a phase II recommended dose of 275 mg/m2 is recommended for further clinical testing.
75
A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides.
Madeleine Duvic,Matthew L. Sherman,Gary S. Wood,Timothy M. Kuzel,Elise A. Olsen,Francine M. Foss,Robert Laliberte,John L. Ryan,Kristilyn Zonno,Alain H. Rook +9 more
TL;DR: In this article, the safety and efficacy of subcutaneous recombinant human IL-12 (rhIL-12) in early mycosis fungoides (MF; stage IA-IIA) in a multi-center, open label clinical trial were evaluated.
68
The role for interleukin-12 therapy of cutaneous T cell lymphoma
Alain H. Rook,Mohamed H. Zaki,Maria Wysocka,Gary S. Wood,Madeleine Duvic,Louise C. Showe,Francine M. Foss,Michael B. Shapiro,Timothy M. Kuzel,Elise A. Olsen,Eric C. Vonderheid,Robert Laliberte,Matthew L. Sherman +12 more
TL;DR: It is suggested that rhIL‐12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses in cutaneous T cell lymphoma trials.
58
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial.
Thomas Powles,Se Hoon Park,Eric Voog,Claudia Caserta,Begoña Perez-Valderrama,Howard Gurney,Yohann Loriot,Srikala S. Sridhar,Norihiko Tsuchiya,Cora N. Sternberg,Joaquim Bellmunt,Jeanny B. Aragon-Ching,Daniel P. Petrylak,Andy Blake-Haskins,Robert Laliberte,Jing Y. Wang,Nuno Costa,Petros Grivas +17 more
TL;DR: Long-term follow-up from the JAVELIN Bladder 100 trial continues to show prolonged OS, and standard-of-care role for avelumab as 1L maintenance in patients with advanced UC that has not progressed with 1L platinum-containing chemotherapy is supported.
32
A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies
Eric J. Feldman,Francis J. Giles,Gail J. Roboz,Karen W.L. Yee,Tania J. Curcio,Victor M. Rivera,Maher Albitar,Robert Laliberte,Camille L. Bedrosian +8 more
TL;DR: This study was undertaken in patients with relapsed or refractory hematologic malignancies to determine the safety and efficacy of AP treatment and to examine if tumoral mTOR pathway status predicts clinical response.
32